Using Astaxanthin to help treat community-acquired pneumonia

Study of the Efficacy and Safety of Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.

This study is testing if adding Astaxanthin, an antioxidant, to the usual treatment can help people with community-acquired pneumonia feel better.

Quick facts

• Phase: PHASE4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Future University in Egypt (other)
• Locations: 1 site (Cairo)
• Trial ID: NCT06334874 on ClinicalTrials.gov

What this trial studies

This study evaluates the efficacy and safety of Astaxanthin, an antioxidant, as an additional treatment for patients with community-acquired pneumonia (CAP). It is a randomized controlled trial conducted at El Matarya Teaching Hospital, where eligible patients will be assigned to receive either Astaxanthin or a placebo alongside standard care. The aim is to determine if Astaxanthin can reduce oxidative stress and improve outcomes in CAP patients. Written informed consent will be obtained from participants or their families prior to enrollment.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with clinical symptoms of community-acquired pneumonia and confirmed lung consolidations on CT scans.

Not a fit: Patients over 70 years old, those with severe immunosuppression, or other significant health issues may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could enhance recovery and reduce complications for patients suffering from community-acquired pneumonia.

How similar studies have performed: While the use of antioxidants in pneumonia treatment is a novel approach, similar studies have shown promise in reducing oxidative stress in other conditions.

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 year
* Clinical: Having symptoms suggestive of CAP such as cough (with or without sputum), fever (\> 38.5°C), pleuritic chest pain or dyspnea.
* Radiologic: consolidations on computed Tomography (CT).

Exclusion Criteria:

* Advanced age (≥70 years old). Presence of severe immunosuppression (HIV infection, use of immune suppressants).

Malignancy. Other concurrent infections, obstruction pneumonia (e.g., because of lung cancer).

Pneumonia developed within two weeks after hospital discharge. Use of ASX before study entry. Hypersensitivity to ASX. Taking warfarin.

* Taking other antioxidants such as vitamin C, vitamin E, glutathione.
* Granulocytopenia (\<1000 neutrophils/mm3).
* Renal failure.
* Liver failure.
* Pregnant and lactating women.
* Hemodynamically unstable patients.

Where this trial is running

Cairo

• Elmatarya Teaching Hospital — Cairo, Egypt (RECRUITING)

Study contacts

• Study coordinator: fatma makram

Conditions: Community-acquired Pneumonia